Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue.
Insight Molecular Diagnostics's Degree of Operating Leverage for the quarter that ended in Jun. 2026 was 0.36. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for Insight Molecular Diagnostics's Degree of Operating Leverage or its related term are showing as below:
IMDX's Degree of Operating Leverage is ranked better than 51.02% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.46
vs IMDX: 0.36
Insight Molecular Diagnostics (NAS:IMDX) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Insight Molecular Diagnostics Degree of Operating Leverage Related Terms
Insight Molecular Diagnostics Degree of Operating Leverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Degree of Operating Leverage Chart
IMDX vs QUCY, BNR, XGN: Degree of Operating Leverage Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Degree of Operating Leverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Degree of Operating Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Operating Leverage of 0.36 mean?
Insight Molecular Diagnostics (IMDX) has a Degree of Operating Leverage of 0.36 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #96 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 49%.
Is Insight Molecular Diagnostics' Degree of Operating Leverage too high?
Insight Molecular Diagnostics' current Degree of Operating Leverage is 0.36. The Medical Diagnostics & Research industry median Degree of Operating Leverage is 0.46. Insight Molecular Diagnostics' value of 0.36 is 21.7% below this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #96 out of 196 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Degree of Operating Leverage compare to QUCY and BNR?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #96 out of 196 companies for Degree of Operating Leverage. This puts Insight Molecular Diagnostics in the upper half of its industry. The industry median Degree of Operating Leverage is 0.46. Insight Molecular Diagnostics' value of 0.36 is 21.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Medical Diagnostics & Research company?
The median Degree of Operating Leverage among Medical Diagnostics & Research companies is 0.46, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Operating Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Degree of Operating Leverage of 0.36 is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Degree of Operating Leverage is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Degree of Operating Leverage is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.08, compared to a current price of $4.13 — trading 282.4% above its estimated fair value. The current Degree of Operating Leverage is 0.36 and 21.7% below the Medical Diagnostics & Research industry median of 0.46. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Degree of Operating Leverage is 0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $4.13 is trading 282.4% above its estimated GF Value™ of $1.08.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Degree of Operating Leverage: 0.36
GF Value™: $1.08 vs. price of $4.13 (282.4% above fair value)
Industry Position: 21.7% below the Medical Diagnostics & Research median (#96 of 196)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
